ERBB2 and breast carcinoma: Despite this, HER2, a well-established contributor to the carcinogenic pathway, undergoes aberrations in several solid tumor types such as breast and stomach cancer implying that it might not serve as a suitable diagnostic indicator for identifying gastric metastasis originating from breast cancer [15].